Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis
Autore:
Farup, PG; Hinterleitner, TA; Lukas, M; Hebuterne, X; Rachmilewitz, D; Campieri, M; Meier, R; Keller, R; Rathbone, B; Oddsson, E;
Indirizzi:
Gjovik Cty Hosp, Gjovik, Norway Gjovik Cty Hosp Gjovik NorwayGjovik Cty Hosp, Gjovik, Norway Karl Franzens Univ Graz, Graz, Austria Karl Franzens Univ Graz Graz Austria Franzens Univ Graz, Graz, Austria Charles Univ, Prague, Czech Republic Charles Univ Prague Czech RepublicCharles Univ, Prague, Czech Republic Hop Archet, Nice, France Hop Archet Nice FranceHop Archet, Nice, France Hadassah Mt Scopus, Jerusalem, Israel Hadassah Mt Scopus Jerusalem Israel dassah Mt Scopus, Jerusalem, Israel S Orsola Univ, Bologna, Italy S Orsola Univ Bologna ItalyS Orsola Univ, Bologna, Italy Kantonsspital, Liestal, Switzerland Kantonsspital Liestal SwitzerlandKantonsspital, Liestal, Switzerland Univ Munster, Med Klin, Munster, Germany Univ Munster Munster GermanyUniv Munster, Med Klin, Munster, Germany Kliniskar Rannsoknastofur, Landspitalinn, Reykjavik, Iceland Kliniskar Rannsoknastofur Reykjavik Iceland italinn, Reykjavik, Iceland
Titolo Testata:
INFLAMMATORY BOWEL DISEASES
fascicolo: 3, volume: 7, anno: 2001,
pagine: 237 - 242
SICI:
1078-0998(200108)7:3<237:M4GDGA>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
5-AMINOSALICYLIC ACID; DUODENAL-ULCER; DRUG-THERAPY; MEDICATION; MAINTENANCE;
Keywords:
clinical trial; patient compliance; drug therapy; inflammatory bowel diseases; mesalazine; ulcerative colitis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Farup, PG NTNU, Unit Appl Clin Res, Keftbygget 5 Etg,Reg Sykeshuset 1, N-7006 Trondheim, Norway NTNU Keftbygget 5 Etg,Reg Sykeshuset 1 Trondheim Norway N-7006
Citazione:
P.G. Farup et al., "Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis", INFLAMM B D, 7(3), 2001, pp. 237-242

Abstract

Background: High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance. The goal of this trial was to compare the effects of mesalazine 4 daily given as prolonged-release granules in packets of I with that of prolonged-release tablets of 0.5 g. Methods: Two hundred twenty-seven patients with mild-to-moderate ulcerative colitis were randomized to treatment with two packets twice daily (Gr-b.i.d.), I packet four times daily (Gr-q.i.d.) or 2 tablets four times daily (Ta-q.i.d.) for 8weeks. A disease activity index (ulcerative colitis disease activity index; UC-DAI) was calculated, and the granules were defined as noninferior to the tablets if the lower limit of the 95% CI for the differences was more than -1 UC-DAI score unit. Results: Noninferiority of the granules compared with the tablets was demonstrated. The mean improvement in the UC-DAI in thetreatment groups Gr-b.i.d., Gr-q.i.d., and Ta-q.i.d. were 3.2, 2.9, and 2.4, respectively; the proportion of complete responders in the three groups 39%, 37%, and 31%, respectively. There were no differences in side effects. Conclusion: Mesalazine 4 g daily given as prolonged-release granules twiceand four times daily is at least as effective as prolonged-release tabletsfour times daily in patients with mild to moderate ulcerative colitis. Thepatients preferred the twice daily closing.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 12:41:51